IP Library › Granted Patent US 12,692,299
Granted Patent B2
US 12,692,299 · App. 18/172,258 · Granted Jul 28, 2026

Variant ICOS ligand immunomodulatory proteins and related compositions and methods

Inventors: Lawrence Evans (Seattle, WA); Michael Kornacker (Seattle, WA); Ryan Swanson (Seattle, WA)
Assignee: Alpine Immune Sciences, Inc.
C07K14/70532A61K35/54A61K38/1774A61K40/11A61K40/22A61K40/31A61K40/418A61K40/4205A61K40/421A61K40/4211C12N5/0681C12N15/85C12P21/02A61K2239/31C07K2319/02C07K2319/03C07K2319/21C07K2319/30C07K2319/31C07K2319/41C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,299
App. No.
18/172,258
Filed
Feb 21, 2023
Granted
Jul 28, 2026
Kind
B2
Art Unit
1674
USPC
424/185.1
Abstract

Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

Claims (6)

1 . A nucleic acid molecule encoding a variant ICOSL-Fc fusion protein comprising a variant ICOSL polypeptide linked via a linker to an Fc region, wherein the variant ICOSL polypeptide is set forth in SEQ ID NO:565, the linker is set forth in SEQ ID NO:229, and the Fc region is set forth in SEQ ID NO:637.

2 . An expression vector comprising the nucleic acid molecule of claim 1 .

3 . A cell comprising the nucleic acid molecule of claim 1 .

4 . A method of producing a variant ICOSL-Fc fusion protein, the method comprising introducing the nucleic acid molecule of claim 1 into a host cell under conditions to express the protein in the cell, and purifying the expressed protein.

5 . The method of claim 4 , wherein the cell is a CHO cell or a derivative thereof.

6 . The method of claim 5 , wherein the CHO cell or derivative thereof is a CHO DG44 cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2023
From: EVANS, LAWRENCE; KORNACKER, MICHAEL; SWANSON, RYAN
To: ALPINE IMMUNE SCIENCES, INC.
Reel/Frame 062783/0651 →
Continuity (4)
Continuation 17560209 · Dec 22, 2021
Continuation 16757344 · Oct 17, 2018
Provisional Application 62574161 · Oct 18, 2017
Related Publication 20230235012A1 · Jul 27, 2023
References Cited (400)
US 5168062A · Stinski · 1992 [cited by applicant]
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5443964A · Pickup et al. · 1995 [cited by applicant]
US 5457035A · Baum et al. · 1995 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5538848A · Livak et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5698530A · Schlom et al. · 1997 [cited by applicant]
US 5716613A · Guber et al. · 1998 [cited by applicant]
US 5716826A · Guber et al. · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5767071A · Palladino et al. · 1998 [cited by applicant]
US 5780426A · Palladino et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5851529A · Guber et al. · 1998 [cited by applicant]
US 5891432A · Hoo · 1999 [cited by applicant]
US 5925517A · Tyagi et al. · 1999 [cited by applicant]
US 5998205A · Hallenbeck et al. · 1999 [cited by applicant]
US 6130316A · Freeman et al. · 2000 [cited by applicant]
US 6143290A · Zhang et al. · 2000 [cited by applicant]
US 6174670B1 · Wittwer et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6218510B1 · Sharpe et al. · 2001 [cited by applicant]
US 6294660B1 · Sharpe et al. · 2001 [cited by applicant]
US 6326145B1 · Whitcombe et al. · 2001 [cited by applicant]
US 6329144B1 · Kubista et al. · 2001 [cited by applicant]
US 6365619B1 · Shi · 2002 [cited by applicant]
US 6428968B1 · Molnar-Kimber et al. · 2002 [cited by applicant]
US 6596535B1 · Carter · 2003 [cited by applicant]
US 6632670B1 · Wadsworth et al. · 2003 [cited by applicant]
US 6635427B2 · Wittwer et al. · 2003 [cited by applicant]
US 6635472B1 · Lauermann · 2003 [cited by applicant]
US 6635750B1 · Coyle et al. · 2003 [cited by applicant]
US 6641809B1 · Linsley et al. · 2003 [cited by applicant]
US 6653103B2 · Peterson et al. · 2003 [cited by applicant]
US 6689871B1 · Wolfe et al. · 2004 [cited by applicant]
US 6723316B2 · Laquerre et al. · 2004 [cited by applicant]
US 6730512B2 · Chang · 2004 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6855317B2 · Koelle et al. · 2005 [cited by applicant]
US 6887471B1 · Linsley et al. · 2005 [cited by applicant]
US 6897045B2 · Engelhardt et al. · 2005 [cited by applicant]
US 6936257B1 · Bennett · 2005 [cited by applicant]
US 6998252B1 · Moss et al. · 2006 [cited by applicant]
US 7001765B2 · Maass et al. · 2006 [cited by applicant]
US 7033826B2 · Perricaudet et al. · 2006 [cited by applicant]
US 7094875B2 · Punnonen et al. · 2006 [cited by applicant]
US 7125717B2 · Carter · 2006 [cited by applicant]
US 7153510B1 · Rose · 2006 [cited by applicant]
US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]
US 7238526B2 · Wilson et al. · 2007 [cited by applicant]
US 7241447B1 · Engelhardt et al. · 2007 [cited by applicant]
US 7247615B2 · Schlom et al. · 2007 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7368116B2 · Schlom et al. · 2008 [cited by applicant]
US 7371826B2 · Presta · 2008 [cited by applicant]
US 7378087B2 · Jefferies et al. · 2008 [cited by applicant]
US 7521532B2 · Dunussi-Joannopoulos et al. · 2009 [cited by applicant]
US 7537924B2 · Coffin · 2009 [cited by applicant]
US 7550296B2 · Hermiston et al. · 2009 [cited by applicant]
US 7588767B2 · Szalay et al. · 2009 [cited by applicant]
US 7588771B2 · Szalay et al. · 2009 [cited by applicant]
US 7612170B2 · Punnonen et al. · 2009 [cited by applicant]
US 7619078B2 · Sharpe et al. · 2009 [cited by applicant]
US 7662398B2 · Szalay et al. · 2010 [cited by applicant]
US 7662627B2 · Johnson et al. · 2010 [cited by applicant]
US 7709214B2 · Freeman et al. · 2010 [cited by applicant]
US 7731952B2 · Mohr et al. · 2010 [cited by applicant]
US 7731974B2 · Bell et al. · 2010 [cited by applicant]
US 7754221B2 · Szalay et al. · 2010 [cited by applicant]
US 7811814B2 · Bohn et al. · 2010 [cited by applicant]
US 7897146B2 · Brown et al. · 2011 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 7927585B2 · Snyder · 2011 [cited by applicant]
US 7943374B2 · Hildinger · 2011 [cited by applicant]
US 7968340B2 · Hallek et al. · 2011 [cited by applicant]
US 8007780B2 · Arbetman et al. · 2011 [cited by applicant]
US 8624010B1 · Yoshinaga · 2014 [cited by applicant]
US 8709417B2 · Allison et al. · 2014 [cited by applicant]
US 8911726B2 · Takahashi et al. · 2014 [cited by applicant]
US 8956619B2 · Ostrand-Rosenberg · 2015 [cited by applicant]
US 9029315B2 · Chen et al. · 2015 [cited by applicant]
US 9103831B2 · O'Sullivan et al. · 2015 [cited by applicant]
US 9375475B2 · Allison et al. · 2016 [cited by applicant]
US 9453227B2 · Diamond et al. · 2016 [cited by applicant]
US 9546207B2 · Kaempfer et al. · 2017 [cited by applicant]
US 9834604B2 · Zhu et al. · 2017 [cited by applicant]
US 10858451B2 · Bernett et al. · 2020 [cited by applicant]
US 10882914B2 · Swanson et al. · 2021 [cited by applicant]
US 11078282B2 · Swanson et al. · 2021 [cited by applicant]
US 11319359B2 · Swanson et al. · 2022 [cited by applicant]
US 11613566B2 · Evans et al. · 2023 [cited by applicant]
US 12110339B2 · Swanson et al. · 2024 [cited by applicant]
US 20020009454A1 · Boone et al. · 2002 [cited by applicant]
US 20020168714A1 · Barbas et al. · 2002 [cited by applicant]
US 20030083246A1 · Cohen et al. · 2003 [cited by applicant]
US 20030138881A1 · Punnonen et al. · 2003 [cited by applicant]
US 20030158102A1 · Chen et al. · 2003 [cited by applicant]
US 20040009604A1 · Zhang et al. · 2004 [cited by applicant]
US 20040063094A1 · Coffin et al. · 2004 [cited by applicant]
US 20040072283A1 · Seed et al. · 2004 [cited by applicant]
US 20040146488A1 · Hu et al. · 2004 [cited by applicant]
US 20050014934A1 · Hinton et al. · 2005 [cited by applicant]
US 20050191296A1 · Kaempfer et al. · 2005 [cited by applicant]
US 20050220818A1 · Lorence · 2005 [cited by applicant]
US 20050260601A1 · Whitt et al. · 2005 [cited by applicant]
US 20060024298A1 · Lazar et al. · 2006 [cited by applicant]
US 20060039894A1 · Mohr et al. · 2006 [cited by applicant]
US 20070098743A1 · Bell et al. · 2007 [cited by applicant]
US 20070110720A1 · Brown et al. · 2007 [cited by applicant]
US 20070202572A1 · Szalay et al. · 2007 [cited by applicant]
US 20070212727A1 · Szalay et al. · 2007 [cited by applicant]
US 20090010889A1 · Brown et al. · 2009 [cited by applicant]
US 20090053244A1 · Chen et al. · 2009 [cited by applicant]
US 20090098529A1 · Chen et al. · 2009 [cited by applicant]
US 20090117034A1 · Chen et al. · 2009 [cited by applicant]
US 20090136917A1 · Szalay et al. · 2009 [cited by applicant]
US 20090155287A1 · Chen et al. · 2009 [cited by applicant]
US 20090162288A1 · Chen et al. · 2009 [cited by applicant]
US 20090215147A1 · Zhang et al. · 2009 [cited by applicant]
US 20090252749A1 · Leister et al. · 2009 [cited by applicant]
US 20090258031A1 · Karrer et al. · 2009 [cited by applicant]
US 20090274728A1 · Brown et al. · 2009 [cited by applicant]
US 20090285860A1 · Martuza et al. · 2009 [cited by applicant]
US 20100062016A1 · Szalay et al. · 2010 [cited by applicant]
US 20100092515A1 · Conner et al. · 2010 [cited by applicant]
US 20100113567A1 · Barber · 2010 [cited by applicant]
US 20100172877A1 · van den Pol et al. · 2010 [cited by applicant]
US 20100178276A1 · Sadelain et al. · 2010 [cited by applicant]
US 20100178684A1 · Woo et al. · 2010 [cited by applicant]
US 20100196325A1 · Szalay et al. · 2010 [cited by applicant]
US 20100233078A1 · Szalay et al. · 2010 [cited by applicant]
US 20100261660A1 · Punnonen et al. · 2010 [cited by applicant]
US 20110064650A1 · Szalay · 2011 [cited by applicant]
US 20110064763A1 · Allen et al. · 2011 [cited by applicant]
US 20110158948A1 · Brown et al. · 2011 [cited by applicant]
US 20110159023A1 · Langermann · 2011 [cited by applicant]
US 20110177032A1 · Martuza · 2011 [cited by applicant]
US 20110195068A1 · Langermann et al. · 2011 [cited by applicant]
US 20110212530A1 · Baltimore et al. · 2011 [cited by applicant]
US 20110293705A1 · Irvine et al. · 2011 [cited by applicant]
US 20130071409A1 · Riley et al. · 2013 [cited by applicant]
US 20130149305A1 · Ostrand-Rosenberg · 2013 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20140050708A1 · Powell et al. · 2014 [cited by applicant]
US 20140099309A1 · Powell et al. · 2014 [cited by applicant]
US 20140154216A1 · Coffin · 2014 [cited by applicant]
US 20140170141A1 · Toporik et al. · 2014 [cited by applicant]
US 20140186380A1 · Gurney · 2014 [cited by applicant]
US 20140186401A1 · Diamond et al. · 2014 [cited by applicant]
US 20140227237A1 · June et al. · 2014 [cited by applicant]
US 20140308299A1 · Allison et al. · 2014 [cited by applicant]
US 20140322129A1 · Leong et al. · 2014 [cited by applicant]
US 20140348832A1 · Zhu et al. · 2014 [cited by applicant]
US 20150104451A1 · Orban · 2015 [cited by applicant]
US 20150232532A1 · Ostrand-Rosenberg · 2015 [cited by applicant]
US 20150266958A1 · Hermans et al. · 2015 [cited by applicant]
US 20150359909A1 · O'Sullivan et al. · 2015 [cited by applicant]
US 20160017018A1 · Wang et al. · 2016 [cited by applicant]
US 20160017041A1 · Violette et al. · 2016 [cited by applicant]
US 20160145344A1 · Akbari · 2016 [cited by applicant]
US 20160158318A1 · Cohen et al. · 2016 [cited by applicant]
US 20160244524A1 · Allison et al. · 2016 [cited by applicant]
US 20160264643A1 · Lazar et al. · 2016 [cited by applicant]
US 20160271218A1 · Biro · 2016 [cited by applicant]
US 20160272707A1 · Levine et al. · 2016 [cited by applicant]
US 20160339066A1 · Szalay et al. · 2016 [cited by applicant]
US 20160340422A1 · Chen et al. · 2016 [cited by applicant]
US 20170028040A1 · Lan et al. · 2017 [cited by applicant]
US 20170042972A1 · Karyekar · 2017 [cited by applicant]
US 20170320959A1 · Swanson et al. · 2017 [cited by applicant]
US 20170369549A1 · Peach et al. · 2017 [cited by applicant]
US 20180244749A1 · Swanson et al. · 2018 [cited by applicant]
US 20180256644A1 · Swanson et al. · 2018 [cited by applicant]
US 20180319861A1 · Lan et al. · 2018 [cited by applicant]
US 20200040059A1 · Swanson et al. · 2020 [cited by applicant]
US 20200283500A1 · Evans et al. · 2020 [cited by applicant]
US 20210139606A1 · Kontermann et al. · 2021 [cited by applicant]
US 20210188995A1 · Swanson et al. · 2021 [cited by applicant]
US 20210363219A1 · Swanson et al. · 2021 [cited by applicant]
US 20220112265A1 · Evans et al. · 2022 [cited by applicant]
US 20220218785A1 · Swanson et al. · 2022 [cited by applicant]
US 20220242930A1 · Swanson et al. · 2022 [cited by applicant]
US 20230101432A1 · Swanson · 2023 [cited by applicant]
US 20230235012A1 · Evans et al. · 2023 [cited by applicant]
EP 0757099 · 1997 [cited by applicant]
EP 1385466 · 2004 [cited by applicant]
EP 1391213 · 2004 [cited by applicant]
EP 1520175 · 2005 [cited by applicant]
EP 1606411 · 2005 [cited by applicant]
EP 1870459 · 2007 [cited by applicant]
EP 2194066 · 2010 [cited by applicant]
EP 3020816 · 2016 [cited by applicant]
EP 3461846A1 · 2019 [cited by applicant]
JP H09202800A · 1997 [cited by applicant]
JP 2014522846A · 2014 [cited by applicant]
JP 2018512856A · 2018 [cited by applicant]
WO WO1993010151 · 1993 [cited by applicant]
WO WO1994011026 · 1994 [cited by applicant]
WO WO1994029351 · 1994 [cited by applicant]
WO WO1998050431 · 1998 [cited by applicant]
WO WO1999038955 · 1999 [cited by applicant]
WO WO1999051642 · 1999 [cited by applicant]
WO WO2000042072 · 2000 [cited by applicant]
WO WO2001030843 · 2001 [cited by applicant]
WO WO2002000717 · 2002 [cited by applicant]
WO 2004030636A2 · 2004 [cited by applicant]
WO WO2004029197 · 2004 [cited by applicant]
WO WO2004056312 · 2004 [cited by applicant]
WO WO2005063816 · 2005 [cited by applicant]
WO WO2005100402 · 2005 [cited by applicant]
WO WO2006019447 · 2006 [cited by applicant]
WO WO2006029879 · 2006 [cited by applicant]
WO 2007011941A2 · 2007 [cited by applicant]
WO WO2007005874 · 2007 [cited by applicant]
WO WO2007052029 · 2007 [cited by applicant]
WO WO2008011636 · 2008 [cited by applicant]
WO WO2008092117 · 2008 [cited by applicant]
WO WO2008155134 · 2008 [cited by applicant]
WO WO2009029342 · 2009 [cited by applicant]
WO WO2009041613 · 2009 [cited by applicant]
WO WO2009067800 · 2009 [cited by applicant]
WO WO2009076524 · 2009 [cited by applicant]
WO WO2009105671 · 2009 [cited by applicant]
WO 2010027827A2 · 2010 [cited by applicant]
WO 2010027828A2 · 2010 [cited by applicant]
WO WO2010077634 · 2010 [cited by applicant]
WO WO2011020024 · 2011 [cited by applicant]
WO WO2011056983 · 2011 [cited by applicant]
WO WO2011066389 · 2011 [cited by applicant]
WO WO2011097477 · 2011 [cited by applicant]
WO WO2011113019 · 2011 [cited by applicant]
WO WO2011133886 · 2011 [cited by applicant]
WO WO2012079000 · 2012 [cited by applicant]
WO WO2012125850 · 2012 [cited by applicant]
WO WO2012140627 · 2012 [cited by applicant]
WO WO2012141984 · 2012 [cited by applicant]
WO WO2012149364 · 2012 [cited by applicant]
WO WO2013003761 · 2013 [cited by applicant]
WO WO2013079174 · 2013 [cited by applicant]
WO WO2013130683 · 2013 [cited by applicant]
WO WO2013149167 · 2013 [cited by applicant]
WO WO2013169338 · 2013 [cited by applicant]
WO WO2014089113 · 2014 [cited by applicant]
WO 2014173975A1 · 2014 [cited by applicant]
WO WO2014198002 · 2014 [cited by applicant]
WO WO2014207063 · 2014 [cited by applicant]
WO WO2015009606 · 2015 [cited by applicant]
WO WO2015107026 · 2015 [cited by applicant]
WO 2015120363A1 · 2015 [cited by applicant]
WO WO2015120363 · 2015 [cited by applicant]
WO WO2015149077 · 2015 [cited by applicant]
WO WO2016008976 · 2016 [cited by applicant]
WO WO2016011083 · 2016 [cited by applicant]
WO WO2016191643 · 2016 [cited by applicant]
WO 2016022468A1 · 2016 [cited by applicant]
WO 2016022994A2 · 2016 [cited by applicant]
WO WO2016022994 · 2016 [cited by applicant]
WO WO2016034678 · 2016 [cited by applicant]
WO WO2016073704 · 2016 [cited by applicant]
WO WO2016118577 · 2016 [cited by applicant]
WO 2016154684A1 · 2016 [cited by applicant]
WO WO2016154684 · 2016 [cited by applicant]
WO WO2016164428 · 2016 [cited by applicant]
WO WO2016168771 · 2016 [cited by applicant]
WO 2017023749A1 · 2017 [cited by applicant]
WO WO2017019846 · 2017 [cited by applicant]
WO WO2017023779 · 2017 [cited by applicant]
WO WO2017034916 · 2017 [cited by applicant]
WO WO2017048878 · 2017 [cited by applicant]
WO WO2017055547 · 2017 [cited by applicant]
WO 2017106061A1 · 2017 [cited by applicant]
WO WO2017181148 · 2017 [cited by applicant]
WO WO2017181152 · 2017 [cited by applicant]
WO WO2017201131 · 2017 [cited by applicant]
WO WO2018022945 · 2018 [cited by applicant]
WO WO2018022946 · 2018 [cited by applicant]
WO WO2018075978 · 2018 [cited by applicant]
WO 2018170021A1 · 2018 [cited by applicant]
WO WO2019079520 · 2019 [cited by applicant]
WO 2019136179 · 2019 [cited by applicant]
WO WO2019241758 · 2019 [cited by applicant]
WO WO2020214867 · 2020 [cited by applicant]
“Database accession No. A0A2K5E9H6,” Retrieved from UNIPROT, https://www.uniprot.org/uniprot/A0A2K5E9H6. Retrieved Sep. 13, 2019. [cited by applicant]
“Database accession No. AER57743 Human B7Rp1 extracellular domain (ECD)” Dated Apr. 19, 2007. [cited by applicant]
“Database accession No. BDH56778,” Retrieved from GENESEQ, Retrieved on Sep. 13, 2019. [cited by applicant]
“Database accession No. BDV07959,” Retrieved from GENESEQ, Retrieved on Sep. 12, 2019. [cited by applicant]
“Database accession No. A0A2J8M811,” Retrieved from UNIPROT, https://www.uniprot.org /uniprot/A0A2J8M811. Retrieved on Mar. 5, 2020. [cited by applicant]
“Database accession No. H9Z6Y0,” version 15. Retrieved from UNISAVE, http://www.ebi.ac.uk/uniprot/unisave/app/#/content/H9Z6Y0/15. Retrieved on Jun. 20, 2017. [cited by applicant]
“Database accession No. L8Y5K4,” version 13. Retrieved from UNISAVE, http://www.ebi.ac.uk/uniprot/unisave/app/#/content/L8Y5K4/13. Retrieved on Sep. 28, 2017. [cited by applicant]
“Database accession No. NP_56074.1,” version 1. Retrieved from NCBI, https://www.ncbi.nlm.nih.gov /protein /NP_056074.1, Retrieved on Mar. 3, 2020. [cited by applicant]
Adler S. et al., “Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjögren's Syndrome: A Pilot Study” Arthritis Care and Research vol. 65, No. 11, Nov. 2013, pp. 18… [cited by applicant]
Alpine Immune Sciences, Inc., “Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vlgD Platform Fused with Trastuzumab Enhanced Immune Responses Agains… [cited by applicant]
Amatore et al., “Inducible Co-Stimulator (ICOS) as a Potential Therapeutic Target for Anti-Cancer Therapy,” Expert Opin Ther Targets. (2018) 22(4): 343-351. [cited by applicant]
Auffermann-Gretzinger et al., “Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients,” Blood. (2002) 99(4): 1442-1448. [cited by applicant]
Baban et al., “Bacteria as vectors for gene therapy of cancer,” Bioeng Bugs. (2010) 1(6):385-394. [cited by applicant]
Banovic et al., “Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells,” J Immunol. (2009) 182(2): 912-920. [cited by applicant]
Benson et al., “GenBank,” Nucleic Acids Res (2013) 41(Database issue):D36-D42. [cited by applicant]
Bowman S.J., et al., “Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj€ogren's Syndrome” Arthiritis and Rheumatology vol. 69, No. 7, Jul. 2017, … [cited by applicant]
Brown et al., “Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis,” J Virol. (1999) 73(11):9011-9020. [cited by applicant]
Bruggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,” J Exp Med. (1987) 166(5):1351-1361. [cited by applicant]
Buchschacher et al., “Human immunodeficiency virus vectors for inducible expression of foreign genes,” J Virol. (1992) 66(5):2731-2739. [cited by applicant]
Burmeister et al., ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol.(2008) 180:774-82. [cited by applicant]
Busch et al., “Dimers, leucine zippers and DNA-binding domains,” Trends Genet. (1990) 6(2): 36-40. [cited by applicant]
Cai, B. et al., “C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo” 2011 Biotechnol Bioeng 108:404-412. [cited by applicant]
Canfield S.M., “The Binding Affinity of Human IgG for its High Affinity Fc Recepor is Determined by Multiple Amino Acids in the CH2 Domain and is Modulated by the Hinge Region” J. Exp. Med. vol. 173, Jun. 1991, pp. 483-… [cited by applicant]
Carsons S.E., et al., “Treatment Guidelines for Rheumatologic Manifestations of Sjorgen's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain” Arthritic Care and Research vol. … [cited by applicant]
Chang et al., “The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists,” Bioorg Med Chem Lett. Jan. 21, 2002;12(2):159-63. [cited by applicant]
Chari et al., “Immunoconjugates containing novel maytansinoids: promising anticancer drugs,” Cancer Res. (1992) 52(1):127-131. [cited by applicant]
Chattopadhyay et al., “Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein,” J … [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci U S A. (1998) 95(2):652-656. [cited by applicant]
Coates L.C., et al., “Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatme… [cited by applicant]
Colby et al., “Engineering antibody affinity by yeast surface display,” Methods Enzymol. 2004;388:348-58. [cited by applicant]
Colcher et al., “Use of monoclonal antibodies as radiopharmaceuticals for the localization of human carcinoma xenografts in athymic mice,” Methods Enzymol. (1986); 121: 802-16. [cited by applicant]
Condomines et al., “Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition,” PLoS One (2015) 10(6):e0130518. [cited by applicant]
Cornetta et al., “No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus,” Hum Gene Ther. (1991) Fall;2(3):215-9. [cited by applicant]
Covassin et al., “Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host diseas… [cited by applicant]
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood. (2004) 103(7):2738-2743. [cited by applicant]
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood. (2003) 101(3):1045-1052. [cited by applicant]
Cunha JS, Gilek-Seibert K. “Systemic Lupus Erythematosus: A Review of the Clinical Approach to Diagnosis and Update on Current Targeted Therapies” R I Med J (2013). 2016;99(12):23-27. Published Dec. 1, 2016. [cited by applicant]
Cutler et al., in [cited by applicant]
David et al., “Protein iodination with solid state lactoperoxidase,” Biochemistry. Feb. 26, 1974;13(5):1014-21. [cited by applicant]
Deeg et al., “The clinical spectrum of acute graft-versus-host disease,” Semin Hematol. (2006) 43(1): 24-31. [cited by applicant]
Deisenhofer et al., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from [cited by applicant]
Del Papa N. et al., “Management of primary Sjgren's syndrome: recent developments and new classificiation criteria” Ther Adv Musculoskel Dis 2018, vol. 10(2) 39-54. [cited by applicant]
Despoix et al., “Mouse CD146/MCAM is a marker of natural killer cell maturation”, Eur J Immunol. (2008) 38(10): 2855-2864. [cited by applicant]
Dick, L. et al., “C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes” 2008 Biotechnol Bioeng 100:1132-1143. [cited by applicant]
Dillon et al., “A Dual ICOS/CD28 Antagonist ICOSL Variant lg Domain (vlgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft GVHD ,” Abstract for 2017 ACR/ARHP Annual Meeting. Arthritis Rheumato… [cited by applicant]
Dillon et al., “A Dual ICOS/CD28 Antagonist ICOSL Variant lg Domain (vlgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft GVHD ,” Presentation for 2017 ACR/ARHP Annual Meeting (Nov. 3-8, 2017… [cited by applicant]
Dillon et al., “Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Mo… [cited by applicant]
Dillon et al., “Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Mo… [cited by applicant]
Dillon et al., “A Dual ICOS/CD28 Antagonist ICOSL Variant lg Domain (vlgDTM) Potently Suppresses Human Mixed Lymphocyte Reactions and Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD),” Abstract for 2018 BMT Tande… [cited by applicant]
Dillon et al., “A Dual ICOS/CD28 Antagonist ICOSL Variant lg Domain (vlgDTM) Potently Suppresses Human Mixed Lymphocyte Reactions and Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD)” Presentation for BMT Tandem … [cited by applicant]
Dillon et al., “Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates In Vivo Efficacy in an Experimental Autoimmune Encephalomyelitis (EAE) Model” Abstract for the American Neurological Association … [cited by applicant]
Dillon et al., “Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates In Vivo Efficacy in an Experimental Autoimmune Encephalomyelitis (EAE) Model” Presentation for the American Neurological Associat… [cited by applicant]
Duncan et al., “The binding site for C1q on lgG,” Nature. Apr. 21, 1988;332(6166):738-40. [cited by applicant]
Duncan, A.R., et al., “Localization of the binding site for the human high-affinity Fc receptor on lgG” 1988 Nature 332:563. [cited by applicant]
Ehx et al., “Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice”, Front Immunol. (2018) 9:1943. [cited by applicant]
Elyoussfi S., et al., “Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies” Rheumatol Int (2016) 36:603-612. [cited by applicant]
Engelman et al., “Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication,” J Virol. 1995 69(5):2729-2736. [cited by applicant]
Ettinger R., et al., “Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-b receptor-lgG1 fusion protein” Proc. Natl. Acad. Sci. USA, vol. 93, pp. 13102-13107, Nov.… [cited by applicant]
Evans et al., “Generation of Novel Immuno-Oncology Biologics via Directed Evolution of Variant lgSF Domains,” Poster Presentation for Immune Checkpoint Inhibitors, Boston, MA (Mar. 14-16, 2017) 1 page. [cited by applicant]
Evans et al., “Novel immunomodulatory proteins generated via directed evolution of variant lgSF domains,” Abstract for AAI Immunology 2017, Washington D.C. (May 12-16, 2017) 1 page Published April A852017. [cited by applicant]
Evans et al., “Novel immunomodulatory proteins generated via directed evolution of variant lgSF domains,” Poster for AAI Immunology 2017, Washington D.C. (May 12-16, 2017) 1 page. [cited by applicant]
Evans et al., “Therapeutic T Cell Activation Using Engineered Variant lgSF Domains,” Abstract for Society for Immunotherapy of Cancer, National Harbor, MD, (Nov. 9-13, 2016) 1 page Published Nov. 8, 2016. [cited by applicant]
Evans et al., “Therapeutic T Cell Activation Using Engineered Variant lgSF Domains,” Poster presented at Society for Immunotherapy of Cancer, National Harbor, MD, (Nov. 9-13, 2016) 1 page. [cited by applicant]
Ferrara et al., “Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease,” Blood. (2011) 118(25): 6702-6708. [cited by applicant]
Ferro F, et al., “One year in review 2017: primary Sogren's syndrome” Clin Exp Rheumatol 2017; 35: 179-191. [cited by applicant]
Forcade et al., “An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition,” JCI Insight. (2017) 2(12): e92111. [cited by applicant]
Ford et al., “Targeting co-stimulatory pathways: transplantation and autoimmunity,” Nat Rev Nephrol. (2014) 10(1):14-24. [cited by applicant]
Fowler et al., “R707, a fully human antibody directed against CC-chemokine receptor 7, attenuates xenogeneic acute graft-versus-host disease”, Am J Transplant. (2019) 19(7): 1941-1954. [cited by applicant]
Fraker et al., “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril,” Biochem Biophys Res Commun. Feb. 28, 1978;80(4):849-57. [cited by applicant]
Freeman et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,” J Exp Med (2000) 192(7):1027-1034. [cited by applicant]
Garcia-Aragoncillo et al., “Design of virotherapy for effective tumor treatment,” Curr Opin Mol Ther. Aug. 2010;12(4):403-11. [cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods. Mar. 28, 1997;202(2):163-71. [cited by applicant]
Gentz et al., “Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains,” Science. (1989) 243(4899): 1695-1699. [cited by applicant]
Gherardi et al., “Recombinant poxviruses as mucosal vaccine vectors,” J Gen Virol. (2005) 86(Pt 11):2925-2936. [cited by applicant]
Gordon, C, et al., “The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults” Rheumatology 2018; 57:e1-e45 advanced publication Oct. 6, 2017. [cited by applicant]
Guerra et al., “Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected Hela cells,” J Virol. (2006) 80(2): 985-98. [cited by applicant]
Hahn H.H. et al., “American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis” Arthritis Care Res. (Hoboken). Jun. 2012; 64(6): 797-808. [cited by applicant]
Hallden et al., “Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets,” Expert Opin Ther Targets. Oct. 2012;16(10):945-58. [cited by applicant]
Harris et al., “CD80 costimulation is essential for the induction of airway eosinophilia,” J Exp Med. Jan. 6, 1997;185(1):177-82. [cited by applicant]
Harris, R. J. “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture” 1995 J Chromatogr A 705:129-34. [cited by applicant]
Hartwell et al., “An early-biomarker algorithm predicts lethal graft-versus-host disease and survival,” JCI Insight. (2017) 2(3): e89798. [cited by applicant]
Hellstrom et al., “Antitumor effects of L6, an lgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci U S A. (1986) 83(18):7059-7063. [cited by applicant]
Hellstrom et al., “Strong antitumor activities of lgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci U S A. (1985) 82(5):1499-1502. [cited by applicant]
Hinman et al., “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics,” Cancer Res. (1993) 53(14):3336-3342. [cited by applicant]
Holdgate N et al., “Recent advances in primary Sjogren's syndrome” [version 1; referees: 3 approved] F1000Research 2016, 5(F1000 Faculty Rev): 1412 Last updated: Jun. 17, 2016. [cited by applicant]
Hoseini et al., “A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia”, Blood Adv. Jun. 12, 2018;2(11):1250-1258. [cited by applicant]
Hu et al., “Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy,” J Virol. (2001) 75(21):10300-10308. [cited by applicant]
Hunter et al., “Preparation of iodine-131 labelled human growth hormone of high specific activity,” Nature. May 5, 1962;194:495-6. [cited by applicant]
Idusogie et al., “Mapping of the C1q binding site on rituxan, a chimeric antibody with a human lgG1 Fc,” J Immunol. (2000) 164(8):4178-4184. [cited by applicant]
Johann et al., “GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus,” J Virol. (1992) 66(3):1635-1640. [cited by applicant]
Kabat et al., “Sequences of Proteins of Immunological Interest,” Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991), 83 pages. [cited by applicant]
Kawalec P, et al., “Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis” Rheumatology International (2018) 38:1… [cited by applicant]
Kirn et al., “Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer,” Nat Rev Cancer. Jan. 2009;9(1):64-71. [cited by applicant]
Kolberg, “Gene-transfer virus contaminant linked to monkey's cancer,” J NIH Res. (1992) 4:43-44. [cited by applicant]
Koura et al., “In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial”, Biol Blood Marrow Transplant. (2013) 19(11): 1638-1649. [cited by applicant]
Koyama et al., “Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells,” Blood. (2009) 113(9): 2088-2095. [cited by applicant]
La Paglia G.M.C. et al., “One year in review 2017: systemic lupus erythematosus” Clin Exp Rheumatol 2017; 35:551-561. [cited by applicant]
Labrijn et al., “Therapeutic lgG4 antibodies engage in Fab-arm exchange with endogenous human lgG4 in vivo,” Nat Biotechnol. Aug. 2009;27(8):767-71. [cited by applicant]
Laouar et al., “STAT3 is required for Flt3L-dependent dendritic cell differentiation,” Immunity. (2003) 19(6): 903-912. [cited by applicant]
Larsen et al., “Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties,” Am J Transplant. Mar. 2005;5(3):443-53. [cited by applicant]
Levin et al., “Novel Immunomodulatory Proteins Generated Via Directed Evolution of Variant lgSF Domains,” Abstract for Keystone Symposia: Immune Regulation in Autoimmunity and Cancer, Whistler, British Columbia, Canada … [cited by applicant]
Levin et al., “Novel Immunomodulatory Proteins Generated Via Directed Evolution of Variant lgSF Domains,” Poster presentation for Keystone Symposia: Immune Regulation in Autoimmunity and Cancer, Whistler, British Columb… [cited by applicant]
Levin et al., “Novel Variant lg Domain (vlgD) Proteins Generated Via Directed Evolution of lgSF Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease,” Abstract for ASH 2017 Nov. 1, 2017 (Dec. … [cited by applicant]
Levin et al., “Novel Variant lg Domain (vlgD) Proteins Generated Via Directed Evolution of lgSF Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease,” Poster for ASH 2017 (Dec. 9-12, 2017). [cited by applicant]
Levin et al., “Tumor-Localizing NKp30/ICOSL vlgD Fusion Proteins Direct Effective Dual CD28/ICOS T cell Costimulation to B7-H6+ Tumor Cells in vitro and Tumors in vivo” Abstract 2018 SITC (Nov. 7-11, 2018) Published Nov… [cited by applicant]
Levin et al., “Tumor-Localizing NKp30/ICOSL vlgD Fusion Proteins Direct Effective Dual CD28/ICOS T cell Costimulation to B7-H6+ Tumor Cells in vitro and Tumors in vivo” Poster 2018 SITC (Nov. 7-11, 2018) Published Nov. … [cited by applicant]
Levin et al., “Tumor-localizing NKp30/ICOSL vlgD fusion proteins direct effective dual CD28/ICOS T cell costimulation to B7-H6+ tumor cells in vitro and tumors in vivo” Abstract SITC 2018. [cited by applicant]
Levin et al., “Novel Immunomodulatory Proteins Generated Via Directed Evolution of Variant lgSF Domains” Keystone Symposia on Molecular and Cellular Biology, Lymphocytes and their Roles in Cancer, Keystone, CO, Feb. 11-… [cited by applicant]
Levin, S.D., et al., “Novel Immunomodulatory proteins generated via directed evolution of variant lgSF domains.” Front Immunol., (2020) 10:3086. [cited by applicant]
Lewis et al., “Novel immunomodulatory proteins generated via directed evolution of variant lgSF domains,” Abstract for Poster Presentation at the Federation of Clinical Immunology Societies Meeting, Chicago IL (Jun. 14,… [cited by applicant]
Lewis et al., “Novel immunomodulatory proteins generated via directed evolution of variant lgSF domains,” Poster Presentation at the Federation of Clinical Immunology Societies Meeting, Chicago IL (Jun. 14, 2017). [cited by applicant]
Li et al., “Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation,” J Transl Med. (2010) 8:104. [cited by applicant]
Li et al., “Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease,” JCI Insight. (2016) 1(6): e86660. [cited by applicant]
Li et al., “Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6,” J Exp Med (2011) 208(4): 703-714. [cited by applicant]
Lin et al., “Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins,” Bioorg Med Chem Lett. Jan. 21, 2002;12(2):133-6. [cited by applicant]